1-deoxynojirimycin has been researched along with g(m2) ganglioside in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Butters, TD; Dwek, RA; Neises, GR; Perry, VH; Platt, FM; Proia, RL; Reinkensmeier, G; Townsend, MJ; Winchester, B | 1 |
| Chavany, C; Jendoubi, M | 1 |
| Butters, TD; Dwek, RA; Jeyakumar, M; Platt, FM | 1 |
| Futerman, AH; Jeyakumar, M; Lloyd-Evans, E; Pelled, D; Platt, FM; Riebeling, C | 1 |
| Baek, RC; Kasperzyk, JL; Platt, FM; Seyfried, TN | 1 |
| Baek, RC; Bronson, RT; Butters, TD; Denny, CA; Heinecke, KA; Kim, YP; Loh, KS; Platt, FM; Seyfried, TN | 1 |
| Arthur, JR; Lee, JP; Seyfried, TN; Snyder, EY | 1 |
| Cardarelli, RA; Chen, Y; Gaval-Cruz, M; Higurashi, N; Hirose, S; Horiuchi, Y; Ishizuka, K; Kai, M; Kano, S; Kato, TA; Koga, M; Kondo, MA; Lee, Y; Maegawa, G; O'Donnell, P; Obie, C; Okano, H; Rapoport, JL; Sawa, A; Sedlak, TW; Seshadri, S; Srivastava, R; Tristan, C; Valle, D; Wilson, AM; Yuan, M | 1 |
| Alméciga-Díaz, CJ; Benincore-Flórez, E; Echeverri-Peña, OY; Espejo-Mojica, AJ; Garzón Jaramillo, RG; Leal, AF; Solano-Galarza, D; Suarez, DA | 1 |
3 review(s) available for 1-deoxynojirimycin and g(m2) ganglioside
| Article | Year |
|---|---|
Biology and potential strategies for the treatment of GM2 gangliosidoses.
Topics: 1-Deoxynojirimycin; Adolescent; Adult; Animals; beta-N-Acetylhexosaminidases; Bone Marrow Transplantation; Cats; Cell Transplantation; Child; Disease Models, Animal; Dogs; G(M2) Ganglioside; Genetic Therapy; Genetic Vectors; Glycolipids; HIV; Humans; Infant; Lysosomes; Mice; Mice, Knockout; Neurons; Phenotype; Point Mutation; Rats; Sandhoff Disease; Swine; Tay-Sachs Disease; Transplantation, Homologous | 1998 |
Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis.
Topics: 1-Deoxynojirimycin; Animals; Bone Marrow Transplantation; Chemotherapy, Adjuvant; Disease Models, Animal; G(M2) Ganglioside; Gangliosides; Glucosylceramides; Glucosyltransferases; Glycosphingolipids; Humans; Lysosomal Storage Diseases; Lysosomes; Mice; Models, Biological; Models, Chemical; Morpholines; Sandhoff Disease; Tay-Sachs Disease; Treatment Outcome | 2002 |
GM2 Gangliosidoses: Clinical Features, Pathophysiological Aspects, and Current Therapies.
Topics: 1-Deoxynojirimycin; beta-N-Acetylhexosaminidases; Blood-Brain Barrier; Clinical Trials as Topic; Diet, Ketogenic; G(M2) Activator Protein; G(M2) Ganglioside; Gangliosidoses, GM2; Genetic Therapy; Humans; Mutation; Pyrimethamine; Stem Cell Transplantation | 2020 |
6 other study(ies) available for 1-deoxynojirimycin and g(m2) ganglioside
| Article | Year |
|---|---|
Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin.
Topics: 1-Deoxynojirimycin; Animals; Blood-Brain Barrier; Brain; Disease Models, Animal; Enzyme Inhibitors; G(M2) Ganglioside; Lysosomes; Mice; Microscopy, Electron; Neurons; Tay-Sachs Disease | 1997 |
Inhibition of calcium uptake via the sarco/endoplasmic reticulum Ca2+-ATPase in a mouse model of Sandhoff disease and prevention by treatment with N-butyldeoxynojirimycin.
Topics: 1-Deoxynojirimycin; Adenosine Triphosphate; Animals; Blotting, Western; Brain; Calcium; Calcium-Transporting ATPases; Cell Death; Disease Models, Animal; Dose-Response Relationship, Drug; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Enzyme Inhibitors; G(M2) Ganglioside; Gangliosides; Genotype; Glycolipids; Hippocampus; Kinetics; Lipid Metabolism; Mice; Mice, Transgenic; Microsomes; Neurons; Reverse Transcriptase Polymerase Chain Reaction; Sandhoff Disease; Sarcoplasmic Reticulum; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Spectrophotometry; Thapsigargin; Time Factors | 2003 |
N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice.
Topics: 1-Deoxynojirimycin; Animals; Animals, Newborn; beta-Hexosaminidase alpha Chain; Brain; Brain Chemistry; Disease Models, Animal; Down-Regulation; G(M2) Ganglioside; Gangliosides; Glycosphingolipids; Mice; Mice, Knockout; Nerve Degeneration; Neuraminidase; Sandhoff Disease; Treatment Outcome | 2008 |
Restricted ketogenic diet enhances the therapeutic action of N-butyldeoxynojirimycin towards brain GM2 accumulation in adult Sandhoff disease mice.
Topics: 1-Deoxynojirimycin; 3-Hydroxybutyric Acid; Analysis of Variance; Animals; beta-N-Acetylhexosaminidases; Blood Glucose; Body Weight; Brain; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Diet, Ketogenic; Eating; G(M2) Ganglioside; Lipid Metabolism; Mice; Mice, Knockout; Myelin Sheath; Purkinje Cells; Sandhoff Disease | 2010 |
Therapeutic effects of stem cells and substrate reduction in juvenile Sandhoff mice.
Topics: 1-Deoxynojirimycin; Animals; beta-N-Acetylhexosaminidases; G(M2) Ganglioside; Hexosaminidase B; Mice; Neural Stem Cells; Sandhoff Disease | 2012 |
Clinical utility of neuronal cells directly converted from fibroblasts of patients for neuropsychiatric disorders: studies of lysosomal storage diseases and channelopathy.
Topics: 1-Deoxynojirimycin; Action Potentials; Basic Helix-Loop-Helix Transcription Factors; Cell Differentiation; Epilepsies, Myoclonic; Fibroblasts; G(M2) Ganglioside; Gene Expression; Genetic Vectors; Glycoside Hydrolase Inhibitors; Humans; Lentivirus; Nerve Tissue Proteins; Neurons; Plasmids; Primary Cell Culture; Tay-Sachs Disease; Transcription Factors; Transduction, Genetic; Transgenes | 2015 |